Besivance (susp)
| Besivance (susp) | ||
|---|---|---|
| DOSAGE | Conjunctivitis: Invert closed bottle and shake once before use. Instill one drop in the affected eye(s) TID, 4 to 12 hours apart x 7 days | |
| Bacterial Keratitis | ||
| Low risk of vision loss: 1 gtts q1-2hr + Optional add on tobramycin or ciprofloxacin ung qHS | ||
| Moderate risk of vision loss: Loading dosage q5min for 5 doses, then q30min until midnight, then q1hr | ||
| Vision-threatening: Consider fortified tobraymycin or gentamicin (15 mg/ml) q1hr, alternating with fortified cefazolin (50mg/ML) or vancomycin (25mg/mL) q1hr. | ||
| GENERIC | besifloxacin 0.6% | |
| SIZE | 5mL | |
| INDICATIONS | BESIVANCE ® (besifloxacin ophthalmic suspension) 0.6%, is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans* CDC coryneform group G Corynebacterium pseudodiphtheriticum* Corynebacterium striatum* Haemophilus influenzae Moraxella catarrhalis* Moraxella lacunata* Pseudomonas aeruginosa* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis* Staphylococcus lugdunensis* Staphylococcus warneri* Streptococcus mitis group Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius* | |
| MECHANISM OF ACTION | Fluoroquinolone (4th), dual-halogenated chlorofluoroquinolone | |
| MICROBIOLOGY | Work against Gram-positive and Gram-negative bacteria due to the inhibition of both bacterial DNA gyrase and topoisomerase IV. | |
| CONTRAINDICATIONS & WARNINGS | Hypersensitivity to any of the ingredients in the formulation. | |
| PEDIATRIC USE | The safety and effectiveness of BESIVANCE in infants below one year of age have not been established. The efficacy of BESIVANCE in treating bacterial conjunctivitis in pediatric patients one year or older has been demonstrated in controlled clinical trials | |
| PREGNANCY | There are no available human data for the use of BESIVANCE during pregnancy to inform any drug-associated risks; however, systemic exposure to besifloxacin from ocular administration is low. Oral administration of besifloxacin to pregnant rats during organogenesis or during the prenatal and postnatal period did not produce adverse embryofetal or offspring effects at clinically relevant systemic exposures | |
| NOTE | BAK preserved. Should shake Suspension prior to use. DuraSite vehicle prolongs contact time. Possible anti-inflammatory action has been suggested. | |